Table 1 Patient characteristics
Characteristics | Total (n = 705) | Training group (n = 509) | Validation group (n = 196) | P value |
|---|---|---|---|---|
Age, years | ||||
 Median (range) | 55 (26—90) | 54 (26—90) | 56 (27—90) | 0.033 |
Menopausal status | ||||
 Premenopausal | 375 (53.2%) | 280 (55.0%) | 95 (48.5%) | 0.119 |
 Postmenopausal | 330 (46.8%) | 229 (45.0%) | 101 (51.5%) |  |
CEA (Ug/L) | ||||
 Average | 2.773 ± 3.269 | 2.619 ± 2.444 | 3.171 ± 4.775 | 0.071 |
CA 125 (Ug/L) | ||||
 Average | 15.012 ± 12.939 | 14.701 ± 14.021 | 15.818 ± 9.560 | 0.028 |
CA 153 (Ug/L) | ||||
 Average | 11.415 ± 9.838 | 11.061 ± 8.538 | 12.335 ± 12.584 | 0.254 |
Tumor size | ||||
 Average | 2.620 ± 1.476 | 2.636 ± 1.480 | 2.579 ± 1.469 | 0.478 |
T category | ||||
 T1 | 330 (46.8%) | 228 (44.8%) | 102 (52.0%) | 0.22 |
 T2 | 337 (47.8%) | 252 (49.5%) | 85 (43.4%) |  |
 T3 | 38 (5.4%) | 29 (5.7%) | 9 (4.6%) |  |
Histology | ||||
 Invasive ductal carcinoma | 601 (85.2%) | 434 (85.3%) | 167 (85.2%) | 0.177 |
 Invasive lobular carcinoma | 26 (3.7%) | 18 (3.5%) | 8 (4.1%) |  |
 Mixed | 30 (4.3%) | 25 (4.9%) | 3 (2.6%) |  |
 Other | 48 (6.8%) | 32 (6.3%) | 16 (8.2%) |  |
Biological subtype | ||||
 Luminal A | 98 (13.9%) | 70 (13.8%) | 28 (14.3%) | 0.604 |
 Luminal B | 449 (63.7%) | 325 (63.9%) | 124 (63.3%) |  |
 Her-2 amplified | 71 (10.1%) | 55 (10.8%) | 16 (8.2%) |  |
 TNBC | 87 (12.3%) | 59 (11.6%) | 28 (14.3%) |  |
Tumor grade | ||||
 Well differentiated, grade 1 | 78 (11.1%) | 51 (10.0%) | 27 (13.8%) | 0.341 |
 Moderately differentiated, grade 2 | 297 (42.7%) | 215 (42.2%) | 82 (41.8%) |  |
 Poorly differentiated, grade 3 | 330 (46.8%) | 243 (47.7%) | 87 (44.4%) |  |
Vascular invasion | ||||
 No | 594 (84.3%) | 428 (84.1%) | 166 (84.7%) | 0.843 |
 Yes | 111 (15.7%) | 81 (15.9%) | 30 (15.3%) |  |
Calcification | ||||
 No | 331 (47.0%) | 244 (47.9%) | 87 (44.4%) | 0.716 |
 Yes | 374 (53.0%) | 265 (52.1%) | 109 (55.6%) |  |
Lymph node metastasis | ||||
 No | 437 (62.0%) | 322 (63.3%) | 115 (58.7%) | 0.261 |
 Yes | 268 (38.0%) | 187 (36.7%) | 81 (41.3%) |  |
Pathologic N category | ||||
 N0 | 437 (62.0%) | 322 (63.3%) | 115 (58.7%) | 0.328 |
 N1 | 159 (22.6%) | 113 (22.2%) | 46 (23.5%) |  |
 N2 | 65 (9.2%) | 41 (8.1%) | 24 (12.2%) |  |
 N3 | 44 (6.2%) | 33 (6.5%) | 11 (5.6%) |  |
ER status | ||||
 No | 160 (22.7%) | 116 (22.8%) | 44 (22.4%) | 0.923 |
 Yes | 545 (77.3%) | 393 (77.2%) | 152 (77.6%) |  |
PR status | ||||
 No | 261(37.0%) | 192 (37.7%) | 69 (35.2%) | 0.535 |
 Yes | 444(63.0%) | 317 (62.3%) | 127 (64.8%) |  |
HER-2 status | ||||
 Negative | 510 (72.3%) | 361 (70.9%) | 149 (76.0%) | 0.175 |
 Overexpressed | 195 (27.7%) | 148 (29.1%) | 47 (24.0%) |  |
Location | ||||
 UOQ | 422 (59.9%) | 294(57.8%) | 128(65.3%) | 0.28 |
 LOQ | 71 (10.1%) | 55(10.8%) | 16(8.2%) |  |
 LIQ | 76 (10.8%) | 60(11.8%) | 16(8.2%) |  |
 UIQ | 114 (16.2%) | 82(16.1%) | 32(16.3%) |  |
 Central | 22 (3.1%) | 18(3.5%) | 4(2.0%) |  |